Log In
Print
BCIQ
Print
Print this Print this
 

CD3xCD123 DART molecule (MGD006)

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBi-specific antibody against CD3 and CD123 developed using Dual-Affinity Re-Targeting (DART) technology
Molecular Target CD3
Mechanism of Action 
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today